Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Deferoxamine for Leptomeningeal Metastases
NCT05184816Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deferoxamine in leptomeningeal metastases (LM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 1 year. Started Dec 2021; status: recruiting.
02
Drugs
deferoxamine
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT05184816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184816.